Contact Us   |   Print Page   |   Sign In   |   Join
News and Press: Industry News

A new biotechnology and pharmaceutical industry commitment to patients and the public

Wednesday, January 29, 2020   (0 Comments)
Posted by: Alisha Brown
Share |

Wethe undersigned leaders in the biotechnology and pharmaceutical industries, academia, and life science investors, recognize that at this pivotal moment in the history of our industry we are at the dawn of a golden age of medicine. We will soon have the ability to treat and cure diseases that have long been untreatable and incurable.

Our industry is unique. We save, extend, and enhance lives by alleviating the scourge of disease. Our mission is to change the course of each individual’s life for the better. To achieve this, we acknowledge that we have a moral obligation to develop the best medicines and ensure that every person who may benefit has access to them.

We need to ensure that we act with the highest integrity and corporate responsibility — always putting the interests of patients first.

 

To fulfill our obligations to patients and to renew trust and confidence in how we deliver on our mission, each of us affirms this New Commitment to Patients, informed by the following core principles and actions:

Ensure Access

  • The pricing of our medicines at launch will reflect innovation and value to patients, and we commit to achieve broad patient access.
  • We believe in growing our businesses with sustainable innovation, and any price increases on our medicines must be reasonable and guided by the need for uninterrupted patient access.
  • To achieve the goal of patient access, we will collaborate with policymakers, pharmacy benefit managers, payers, and providers to find ways to limit or eliminate copays and deductibles for all patients.
  • We will support generic and biosimilar approvals of safe and effective medicines after legitimate patent and regulatory protections expire.
  • We will seek to collaborate with all key parties in the health care system, including all biopharmaceutical companies, pharmacy benefit managers, payers, hospitals, pharmacies, distributors, and policymakers, to ensure that all patients get access to the medicines they need.

Act with Integrity and Responsibility

  • We support only ethical business practices that drive innovation, competition, and patient choice.
  • We will invest only in novel therapies that address unmet patient needs.
  • We commit to patient advocacy in how we build and operate our companies, and to connecting directly with patients and their families.
  • We will speak out about and not tolerate companies and other stakeholders who abuse this commitment to patients, and who abuse policies aimed at fairly rewarding innovation.

By supporting this New Commitment to Patients, we express our conviction that we must develop medicines with patients as our primary concern. We are confident that in doing so we will best serve the interests of patients, their caregivers, and health care providers, as well as those of our shareholders and society at large.

Co-authors* (listed alphabetically):

John Crowley, J.D., Chairman and CEO, Amicus Therapeutics, Cranbury, NJ

Paul Hastings, CEO, Nkarta Therapeutics, South San Francisco, CA

Rachel King, CEO, GlycoMimetics, Inc., Rockville, MD

Jeremy Levin, D.Phil., M.B. B.Chir., Chairman and CEO, Ovid Therapeutics, New York, NY

Ted Love, M.D., CEO, Global Blood Therapeutics, South San Francisco, CA

John Maraganore, Ph.D., CEO, Alnylam Pharmaceuticals, Cambridge, MA

Cosigners* (listed alphabetically)

Chris Adams, Ph.D.Founder and CEO, Cydan II Inc, Cambridge, MA

Bonnie AndersonChairman and CEO, Veracyte, Inc., South San Francisco, CA

Armando AnidoChairman and CEO, Zynerba Pharmaceuticals, Inc., Devon, PA

Christopher R. Anzalone, Ph.D.President and CEO, Arrowhead Pharma, Pasadena, CA

Mara G. AspinallCEO, Health Catalysts Group, Tuscon, AZ

James E. AudiaVisiting Scholar, Northwestern University, Chicago, IL

Fouad Azzam, Ph.D.Board Member and Venture Capitalist, Nkarta Therapeutics, South San Francisco CA and Weston, MA

Martin BablerPresident and CEO, Principia Biopharma Inc., South San Francisco, CA

Michael P. BaileyPresident and CEO, AVEO Oncology, Cambridge, MA

Stephane BancelCEO, Moderna Inc., Cambridge, MA

Christiana BardonPortfolio Manager, Burrage Capital, Boston, MA

Peter BarrettPartner, Atlas Venture, Cambridge, MA

Charles M. Baum, M.D.President and CEO, Mirati Therapeutics, San Diego, CA

Franklin M. BergerManaging Director, FMB Research, New York, NY

Nessan Bermingham, Ph.D.President and CEO, Triplet Therapeutics, Boston, MA

Jeffrey Bird, M.D.Managing Director, Bluebird Ventures, Palo Alto, CA

Kevin BittermanPartner, Atlas Venture, Cambridge, MA

Lynn D. BleilMember of the Board of Directors, Amicus Therapeutics, Alcon, Sonova, AG, Stericycle, Salt Lake City, UT

Robert BlumPresident and CEO, Cytokinetics, Inc., South San Francisco, CA

Michael BonneyMember of the Board of Directors, Alnylam Pharmaceuticals and Magenta, Boston, MA

Bruce BoothPartner, Atlas Venture, Cambridge, MA

Katrine S. BosleyChairman of the Board, Arrakis Therapeutics, Cambridge, MA

Marina BozilenkoManaging Director, William Blair and Company, Boston, MA

Daniel BradburyChairman and CEO, Equillium, Inc., La Jolla, CA

Steven K. BrauerChairman, Salus Discovery, San Diego, CA

Laura A. BregeMember of the Board of Directors, Portola Pharmaceuticals, Dynavax, Acadia Pharmaceuticals, and Mirum Pharmaceuticals, Valley, CA

John P. ButlerPresident and CEO, Akebia Therapeutics, Cambridge, MA

Brook ByersPartner, Kleiner Perkins, Menlo Park, CA

Barry J. Byrne, M.D.Professor of Pediatrics, University of Florida, Gainsville, FL

George ChurchProfessor, Harvard Medical School, Boston, MA

Chip ClarkPresident and CEO, Genocea, Cambridge, MA

Nathalie Clement, Ph.D.Associate Professor of Pedicatrics, University of Florida, Gainsville, FL

Ron Cohen, M.D.President and CEO, Acorda Therapeutics, Inc., Ardsley, NY

Charles L. CooneyRobert T. Haslam Professor of Biochemical Engineering, Emeritus, Massachusetts Institue of Technology, Cambridge, MA

Manuela Corti, PT, Ph.D.Associate Professor of Pedicatrics, University of Florida, Gainsville, FL

Bernard CouliePresident and CEO, Pliant Therapeutics, San Francisco, CA

Gerald F. Cox, M.D.Staff Physician in Genetics, Boston Children’s Hospital, Boston, MA

Alan CraneEntrepreneur Partner, Polaris Partners, Boston, MA

Roger Crystal, M.D., CEO, Opiant , Santa Monica, CA

Sally J. CurleyCEO, CGIR, LLC, Savannah, GA

Daniel A. de BoerCEO, ProQR Therapeutics, Cambridge, MA

Steven R. Deitcher, M.D.President, CEO, Radimmune Therapeutics, Inc., San Mateo, CA

Thomas J. DesRosieEVP, Chief Legal Officer, Seres Therapeutics, Cambridge, MA

Douglas DoerflerFounder, President and CEO, MaxCyte, Inc., Gaithersburg, MA

Ashley Dombkowski, Ph.D.CEO and Co-founder, Alladapt Immunotherapeutics, Inc., Menlo Park, CA

Daniel DornbuschCEO, Exision Bio Therapeutics, Oakland, CA

Dipal DoshiCEO, Entrada Therapeutics, Boston, MA

Richard H. DouglasChairman of the Board, Aldeyra Therapeutics, Southborough, MA

Steve ElmsManaging Partner, Aisling Capital LLC, New York, NY

Stephen H. Embury, M.D., Founder, CEO and Chairman, Vanguard Therapeutics, Inc., Half Moon Bay, CA

Mark J. EnyedyPresident and CEO, ImmunoGen, Inc., Boston, MA

David R. EpsteinManaging Director, Remedii LLC, Sunny Isles Beach, FL

Robert EssnerExecutive Chairman, Elucida Oncology, Sarasota, FL

Alan EzekowitzCEO, Abide Therapeutics, San Diego, CA

Douglas FambroughPresident and CEO, Dicerna Pharmaceuticals, Lexington, MA

Stephen J. Farr, Ph.D.President and CEO, Zogenix, Inc., Emeryville, CA

Wainwright FishburnGlobal Head, Digital Health, Vice Chair, Path Institute, San Diego, CA

Alexandria ForbesCEO, MeiraGTx, New York, NY

JF FormelaPartner, Atlas Venture, Cambridge, MA

Kaye FosterSenior Advisor, The Boston Consulting Group, San Mateo, CA

Jackie FouseCEO, Agios Pharmaceuticals, Cambridge, MA

Frederick FrankChairman, Evolution Life Science Partners, New York, NY

Martin FriedmanManaging Member, Pharmakon Advisors, LP, New York, NY

Nicholas Galakatos, Ph.D.Head, Blackstone Life Sciences, Cambridge, MA

Ilan GanotFounder, President and CEO, Solid Biosciences, Cambridge, MA

Jason GardnerCEO and President, Magenta Therapeutics, Cambridge, MA

Scott GarlandPresident and CEO, Portola Pharmaceuticals, Corte Madera, CA

Georges GemayelIndependent Board Member, Sudbury, MA

James A. GeraghtyChairman, Orchard Therapeutics, Boston, MA

David V. GoeddelManaging Partner, The Column Group, San Francisco, CA

Mark A. Goldberg, M.D.Member of the Board of Directors, Blueprint Medicines, Cambridge, MA

Robert  J. Gould, Ph.D.President and CEO, Fulcrum Therapeutics, Inc., Cambridge, MA

Kurt GravesChairman, President and CEO, Intarcia Therapeutics, Boston, MA

David GrayzelPartner, Atlas Venture, Cambridge, MA

Barry GreenPresident, Alnylam Pharmaceuticals, Boston, MA

Yvonne GreenstreetCOO, Alnylam Pharmaceuticals, Philaelphia, PA

Sheila Gujrathi, M.D.President and CEO, Gossamer Bio, San Diego, CA

John HaganCEO, Regulus, La Jolla, CA

David HallalChairman and CEO, ElevateBio and AlloVir, Cambridge, MA

Faheem HasnainChairman, Gossamer Bio and Mirati Therapeutics, San Diego, CA

John E. HawkinsAuthor, “Conscience & Courage,” Charlottesville, VA

Russell HerndonCEO, MediSix Therapeutics, Boston, MA

Richard Heyman, Ph.D.Chairman and Co-founder, ORIC Pharmaceutical, San Diego, CA

Steven H. HoltzmanCEO, Decibel Therapeutics, Boston, MA

Wende HuttonGeneral Partner, Canaan Partners, Menlo Park, CA

Douglas S. IngramPresident and CEO, Sarepta Therapeutics, Cambridge, MA

Steven P. JamesPresident and CEO, PIONYR Immunotherapeutics, Inc., South San Francisco, CA

John H. JohnsonCEO, Melinta Therapeutics, FL

Kevin JudiceCEO, DiCE Molecules, Half Moon Bay, CA

Emil KakkisM.D., President, CEO and Founder, Ultragenyx Pharmaceutical, Novato, CA

Johanne KaplanChief Development Officer, ProMIS Neurosciences, Cambridge, MA

Perry KarsenChair, Board of Directors, Jounce Therapeutics and Intellia Therapeutics, Palo Alto, CA

Edward M. Kaye, M.D.CEO, Stoke Therapeutics, Bedford, MA

Laurie KeatingExecutive Vice President and Chief Legal Officer, Alnylam Pharmaceuticals, Inc., Cambridge, MA

Nina KjellsonGeneral Partner, Canaan, Sausalito, CA

Marc KozinIndependent Board Member, Naples, FL

Samarth Kulkarni, Ph.D.CEO, CRISPR Therapeutics AG, Cambridge, MA

Neil KumarCEO, BridgeBio Pharma and Eidos Therapeutics, Palo Alto, CA

Lou Lange, M.D.Former Chairman and CEO, CV Therapeutics, San Francisco, CA

Robert LangerInstitute Professor, Massachusetts Institute of Technology, Cambridge, MA

Donna L. LaVoieCEO, LaVoieHealthScience, Boston, MA

Jeff LeerinkCEO, SVBLeerink, Boston, MA

Nick LeschlyChief, Bluebird Bio, Cambridge, MA

Mark LevinPartner, Third Rock Ventures, Boston, MA

Christine LindenboomVice President, Investor Relations and Corporate Communications, Alnylam Pharmaceuticals, Winchester, MA

Patrick Lu, Ph.D.President and CEO, Sirnaomics, Inc., Gaithersburg, MD

Nagesh MahanthappaCEO and President, Scholar Rock, Cambridge, MA

Ram MandalamCEO and President, Cellerant Therapeutics, San Carlos, CA

Kiran Mazumdar-ShawChairperson, Biocon Ltd, New York, NY

James McArthur, Ph.D.Founder and President, R&D Cydan Inc & Founder and Director Imara Inc, Cambridge, MA

Geoff McDonough, M.D., President and CEO, Generation Bio, Cambridge, MA

David J. McLachlanFormer VP Finance, Genzyme Corp, Former Corporate Director, Dyax Corp, Chelmsford, MA

Dick MeijerCEO, RareM.D. Inc, Carlsbad, CA

Steven J. Mento, Ph.D.President and CEO, Conatus Pharmaceuticals, San Diego, CA

Garry Menzel, Ph.D.President and CEO, TCR Therapeutics, Cambridge, MA

Jim MeyersMember of the Board of Directors, Sangamo Therapeutics, Hillsborough, CA

Rachel MeyersEntrepreneur-in-Residence, Third Rock Ventures, Newton, MA

Jill C. Milne, Ph.D.President and CEO, Catabasis Pharmaceuticals, Boston, MA

Kenneth I. MochPresident and CEO, Cognition Therapeutics, Inc., Pittsburgh, PA

Brett MoniaCEO, Ionis Pharmaceuticals, Carlsbad, CA

Bob MorePartner, Alta Partners, Seattle, WA

Scott W. MorrisonBoard Member and Advisor, Ernst & Young, Hillsborough, CA

Briggs W. Morrison, M.D.CEO, Syndax Pharmaceuticals, Waltham, MA

Robert MulroyPresident and CEO, Partner Therapeutics, Inc., Lexington, MA

Amit D. MunshiDirector, President & CEO Arena Pharmaceuticals Inc., San Diego, CA

Mark MurckoChief Scientific Officer, Dewpoint Therapeutics, Holliston, MA

Mike NarachiPresident and CEO, CODA Biotherapeutics, Santa Barbara, CA

Amir NashatManaging Partner, Polaris Partners, Boston, MA

William J. NewellCEO, Sutro Biopharma, Inc., South San Francisco, CA

Steven Nichtberger, M.D., Chairman and CEO, Cabaletta Bio, Philadelphia, PA

Bernat OlleCEO, Vedanta Biosciences, Inc., Cambridge, MA

John E. OsbornVenture Partner, BioVentures MedTech Funds, Wellesley, MA

Julia C. Owens, Ph.D.President and CEO, Milendo Therapeutics, Ann Arbor, MI

Paris PanayiotopoulosSenior Managing Director, Blackstone Life Sciences, Cambridge, MA

Stelios Papadopoulos, Ph.D.Chairman of the Board of Directors, Biogen, Inc., Exelixis, Inc., Regulus Therapeutics, Inc., Great Neck, NY

Stewart ParkerChairman, ARM Foundation for Cell and Gene Medicine, Principal, Parker BioConsulting, Chapel Hill, NC

Kush M. ParmarManaging Partner, 5AM Ventures, Boston, MA

Brian J G PereiraCEO, Visterra, Inc., Waltham, MA

Mark PerryIndependent Director, Global Blood Therapeutics and Chair, MyoKardia, Inc., Mill Valley, CA

Cary G. Pfeffer, M.D.Partner, Third Rock Ventures, Lexington, MA

William J. Polvino, M.D.CEO, Bridge Medicines, Jacob S. Lasdon House, New York, NY

Richard PopsChairman and CEO, Alkermes PLC, Dublin, Ireland

Mark Pruzanski, M.D.President and CEO, Intercept Pharmaceuticals Inc, New York, NY

Dennis J. PurcellFounder, Aisling Capital LLC, Rye, NY

David E.I. PyottMember of the Board of Directors, Alnylam Pharmaceuticals, Cambridge, MA

Michael G. RaabPresident and CEO, Ardelyx, Inc., Fremont, CA

Paula RaganCEO, X4 Pharmaceuticals Inc., Cambridge, MA

Amit Rakhit, M.D.President and CMO, Ovid Therapeutics, New York, NY

Bill RastetterChairman, Neurocrine Biosciences and Fate Therapeutics and Dare Bioscience, Rancho Santa Fe, CA

Jigar RaythathaPresident and CEO, Constellation Pharmaceuticals, Cambridge, MA

Laurence ReidEntrepreneur in Residence, Third Rock Ventures, Cambridge, MA

Ron RenaudCEO, Translate Bio, Lexington, MA

Hollings RentonMember of the Board of Directors, Portola Pharmaceuticals, AnaptysBio and Zymeworks, Bend, Oregon

Jason RhodesPartner, Atlas Venture, Cambridge, MA

Michael RichmanPresident and CEO, NextCure, Inc., Beltsville, MD

Chris E. RiveraChairman and CEO, Emulate Therapeutics, Inc., Seattle, WA

Howard RobinPresident and CEO, Nektar Therapeutics, San Francisco, CA

Stephanie Rooijen, M.D.CEO, Dynacure, Strasbourg, France

William J. RutterChairman and CEO, Synergenics, LLC, San Francisco, CA

James SapirsteinPresident and CEO, AzurRx BioPharma, Delary Beach, FL

Glenn SblendorioPresident and CEO, iVeric Bio Inc., New York, NY

George Scangos, Ph.D.CEO, Vir Bio, SanFrancisco, CA

John A. Scarlett, M.D.Chairman and CEO Geron Corporation, Menlo Park, CA

Drew SchiffManaging Partner, Aisling Capital LLC, New York, NY

Hans Schikan, PharmDFormer CEO Prosena, CoFounder & Board Member, Pharvaris, Amsterdam, The Netherlands

Stuart L. Schreiber, Ph.D.Loeb Professor, Harvard University, Boston, MA

Amy SchulmanManaging Partner, Polaris Partners, New York, NY

Paul SekhriPresident and CEO, eGenesis, Inc., New York, NY

Alpna SethCEO and President, Proneurotech, San Francisco, CA

Eric ShaffPresident and CEO, Seres Therapeutics, Cambridge, MA

Stephen A. Sherwin, M.D.Clinical Professor of Medicine, UCSF, San Francisco, CA

Jay M. Short, Ph.D.Chairman, CEO, Co-founder, BioAlta, San Diego, CA

Mark Simon, Co-founder, Torreya Parters, New York NY

Nancy SimonianCEO, Syros Pharmaceuticals, Wayland, MA

Vikas SinhaCFO, ElevateBio and AlloVir, Boston, MA

Moncef SlaouiPartner, Medicxi Venture Capital Firm, Gladwyne, PA

Julie Anne SmithPresident and CEO, E-Scape Bio, Inc., South San Francisco, CA

Erika R. SmithCEO, ReNetX Bio, Inc., New Haven, CT

Jean-Pierre Sommadossi, Ph.D.Chairman and CEO, Atea Pharmaceuticals, Inc., Boston, MA

Paula SoteropoulosMember of the Board of Directors, uniQure (former CEO Akcea Therapeutics), Boston, MA

Harald F. Stock, Ph.D.Co-founder, CognifiSense, Inc., Park City, UT

Clifford J. StocksCEO, OncoResponse Inc., Seattle, WA

Markus StoffelProfessor, Swiss Federal Institute of Technology, ETH Zurich, Zurich, Switzerland

David Stump, M.D.Member of the Board of Directors, Portola Pharmaceuticals, Sunesis Pharmaceuticals, Macrogenics, and REGENXBIO, Potomac, MD

Marshall Summar, M.D.Director, Rare Disease Institute, Children’s National Medical Center, Washington, DC

Mary T. SzelaCEO, TriSalus Life Sciences, Westminister, CO

Robert Tepper, M.D.Partner, Third Rock Ventures, Weston, MA

Mark TimneyCEO, The Medicines Company, Parsippany, NJ

Matthew C. TindallCo-founder, President and CEO, Flightpath Biosciences, Inc., Berkeley, CA

Praveen TipirneniCEO, Morphic Therapeutic, Lexington, MA

Andre TurenneCEO, Voyager Pharmaceuticals, Cambridge, MA

Arthur Tzianabos, Ph.D.President and CEO, Homology Medicines, Inc., Bedford, MA

Rogerio Vivaldi, M.D.President and CEO, Sigilon Therapeutics, Cambridge, MA

Alan WaltsExecutive Chairman, Artax Biopharma, Charlestown, MA

Neil WarmaCEO/General Manager, I-Mab Biopharma U.S., Rockville, MD

Gregory T. Went, Ph.D.Founder, Strategic Advisor, Adamas Pharmaceuticals, Independent Consultant, San Francisco, CA

Wendell Wierenga, Ph.D.Chairman, Crinetics Pharmaceuticals Inc., San Diego, CA

Eugene WilliamsExecutive Chairman, ProMIS Neurosciences, Cambridge, MA

Douglas E. Williams, Ph.D.President and CEO, Codiak BioSciences, Cambridge, MA

Matt WilseyCEO, Grace Science, LLC, San Francisco, CA

James M. Wilson, M.D.Rose H Weiss Professor and Director of the Orphan Disease Center, University of Pennsylvania, Philaelphia, PA

Rick WinninghamChairman and CEO, Theravance BioPharma, Inc., South San Francisco, CA

Peter WirthChairman, Syros Pharmaceuticals, Inc; FORMA Therapeutics Holdings, Inc, Boston, MA

Ward WolffMember of the Board of Directors, Portola Pharmaceuticals, Calithera Biosciences and Sunesis Pharmaceuticals, Greenbrae, CA

Kleanthis G. XanthopoulosPresident and CEO, IRRAS, San Diego, CA

Angie YouCEO, Amunix Pharmaceuticals, Mountain View, CA

Bradford ZakesPresident and CEO/BIO Board Member, Cerevast Medical, Inc., Bothell, WA

Elias A. Zerhouni, M.D.Emeritus Professor, Johns Hopkins University, Baltimore, MD

Sandy ZweifachChairman, Palladio Bioscience, Inc., Sausalito, CA

* The signatures above do not necessarily reflect the policies or positions of the agencies, organizations, employers, or companies with which the signers are affiliated.

 

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal